Dr. King is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3300 Gallows Rd
Falls Church, VA 22042Phone+1 703-776-4003Fax+1 703-776-7113
Summary
- Dr. Christopher King is a pulmonologist and critical care physician in Falls Church, VA and is affiliated with Inova Fairfax Medical Campus. He received his medical degree from University of Maryland School of Medicine and has been in practice for over 10 years. He specializes in critical care medicine, cystic fibrosis, interstitial lung diseases, and pulmonary vascular medicine and is experienced in respiratory failure, transplant pulmonology, interstitial lung disease, pulmonary arterial hypertension, and cystic fibrosis. He currently serves as the Associate Medical Director of the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital. He is also the Chief of Cardiovascular Critical Care for the Inova Schar Heart and Vascular Institute.
Education & Training
- National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 2006 - 2009
- National Capital ConsortiumResidency, Internal Medicine, 2002 - 2005
- University of Maryland School of MedicineClass of 2002
Certifications & Licensure
- VA State Medical License 2004 - 2026
- VA State Medical License 2004 - 2026
- SD State Medical License 1900 - 2013
- IA State Medical License 2012 - 2012
- IA State Medical License 2012 - 2012
- PA State Medical License 2011 - 2012
- PA State Medical License 2011 - 2012
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
- Join now to see all
Clinical Trials
- Non-Invasive Measurement of Respiratory Effort Start of enrollment: 2007 Feb 01
- Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD Start of enrollment: 2018 Feb 18
Roles: Contact, Principal Investigator
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsHospitalization Rates in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Registry.Christopher S King, Rosalinda V Ignacio, Vikramjit Khangoora, Alan Nyquist, Anju Singhal
American Journal of Respiratory and Critical Care Medicine. 2024-09-15 - 1 citationsPulmonary matrix-derived hydrogels from patients with idiopathic pulmonary fibrosis induce a proinflammatory state in lung fibroblasts in vitro.Jorge G Fernandez Davila, Amit K Singh, Durwood W Moore, Joseph Kim, Jawad A Khan
Molecular Biology of the Cell. 2024-08-01 - 8 citationsAntithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021.Scott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, Kevin Doerschug, Geert-Jan Geersing
Chest. 2024-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: